Jason Powell

Dr Jason Powell

Centre for Cancer Biology

College of Health

Dr Jason Powell Centre for Cancer Biology, Adelaide Molecular Biology, Cell Biology, Biotechnology Adjunct Senior Research Fellow School of Pharmacy and Medical Sciences The University of South Australia

Year Citation
2025 Powell, J. A., & Pitson, S. M. (2025). Sphingosine 1-phosphate signalling in cancer stem cells. Oncogenesis, 14(1), 1-10.
DOI
2024 Li, M., Bennett, M. K., Toubia, J., Pope, V. S., Tea, M. N., Tamang, S., . . . Pitson, S. M. (2024). An orthotopic syngeneic mouse model of bortezomib-resistant multiple myeloma. British Journal of Haematology, 204(2), 566-570.
DOI Scopus1 WoS1 Europe PMC1
2024 Kan, W. L., McClure, B. J., Hahn, C. N., & Powell, J. A. (2024). The 10th Barossa meeting: cell signalling to cancer medicine. Cell Death and Disease, 15(3, article no. 230), 1-3.
DOI
2024 Nwosu, G. O., Ross, D. M., Powell, J. A., & Pitson, S. M. (2024). Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia. Cell Death and Disease, 15(6, article no. 413), 413-1-413-11.
DOI Scopus27 WoS24 Europe PMC24
2023 Conn, V. M., Gabryelska, M., Toubia, J., Kirk, K., Gantley, L., Powell, J. A., . . . Conn, S. J. (2023). Circular RNAs drive oncogenic chromosomal translocations within the MLL recombinome in leukemia. Cancer Cell, 41(7), 1309-1326.e10.
DOI Scopus51 WoS50 Europe PMC47
2023 Subramanian, S., Thoms, J. A. I., Huang, Y., Cornejo Paramo, C. P., Koch, F. C., Jacquelin, S., . . . Pimanda, J. E. (2023). Genome-wide transcription factor-binding maps reveal cell-specific changes in the regulatory architecture of human HSPCs. Blood, 142(17), 1448-1462.
DOI Scopus30 WoS30 Europe PMC40
2022 Bassal, M. A., Samaraweera, S. E., Lim, K., Benard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia.. Nat Commun, 13(1), 4131.
DOI Scopus2 WoS2 Europe PMC1
2022 Nwosu, G. O., Powell, J. A., & Pitson, S. M. (2022). Targeting the integrated stress response in hematologic malignancies.. Experimental Hematology & Oncology, 11(1), 94.
DOI Scopus12 WoS14 Europe PMC13
2022 Pitman, M. R., Lewis, A. C., Davies, L. T., Moretti, P. A. B., Anderson, D., Creek, D. J., . . . Pitson, S. M. (2022). The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism. Scientific Reports, 12(1), 454-1-454-12.
DOI Scopus15 WoS13 Europe PMC12
2022 Lewis, A. C., Pope, V. S., Tea, M. N., Li, M., Nwosu, G. O., Nguyen, T. M., . . . Pitson, S. M. (2022). Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.. Blood, 139(26), 3737-3751.
DOI Scopus37 WoS32 Europe PMC35
2022 Bassal, M. A., Samaraweera, S. E., Lim, K., Bernard, B. A., Bailey, S., Kaur, S., . . . D'Andrea, R. J. (2022). Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia. Nature Communications, 13(1), 1-12.
DOI Scopus18 WoS19 Europe PMC16
2021 Lewis, A. C., Wallington-Beddoe, C. T., Powell, J. A., & Pitson, S. M. (2021). Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies (vol 4, 72, 2018). CELL DEATH DISCOVERY, 7(1), 2 pages.
DOI
2021 Bennett, M. K., Li, M., Tea, M. N., Pitman, M. R., Toubia, J., Wang, P. P. -S., . . . Pitson, S. M. (2021). Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.. Neoplasia, 24(1), 1-11.
DOI Scopus16 WoS16 Europe PMC13
2020 Morrish, E., Copeland, A., Moujalled, D. M., Powell, J. A., Silke, N., Lin, A., . . . Brumatti, G. (2020). Clinical MDR1 inhibitors enhance Smac-mimetic bioavailability to kill murine LSCs and improve survival in AML models. Blood Advances, 4(20), 5062-5077.
DOI Scopus10 WoS9 Europe PMC9
2019 Neubauer, H. A., Tea, M. N., Zebol, J. R., Gliddon, B. L., Stefanidis, C., Moretti, P. A. B., . . . Pitson, S. M. (2019). Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. Oncogene, 38(8), 1151-1165.
DOI Scopus26 WoS24 Europe PMC18
2019 Powell, J. A., Pitman, M. R., Zebol, J. R., Moretti, P. A., Neubauer, H. A., Davies, L. T., . . . Pitson, S. M. (2019). Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1. The Biochemical Journal, 476(21), 3211-3226.
DOI Scopus14 WoS14 Europe PMC12
2019 Wallington-Beddoe, C., Xie, V., Tong, D., Powell, J., Lewis, A., Davies, L., . . . Bendall, L. (2019). Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia. British Journal of Haematology, 184(3), 443-447.
DOI Scopus13 WoS13 Europe PMC13
2018 Lewis, A. C., Wallington-Beddoe, C. T., Powell, J. A., & Pitson, S. M. (2018). Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies. Cell Death Discovery, 5(1), 4.
DOI Scopus63 WoS66 Europe PMC56
2018 Pitson, S. M., & Powell, J. A. (2018). Modification of the tumour microenvironment via exosomal shedding of sphingosine 1-phosphate receptor 2 by breast cancer cells. OncoTarget, 9(57), 30938-30939.
DOI Scopus2 Europe PMC2
2017 Powell, J. A., Wallington Beddoe, C. T., & Pitson, S. M. (2017). Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic. International journal of hematologic oncology, 6(2), 31-34.
DOI Europe PMC6
2017 Powell, J. A., Lewis, A. C., & Pitson, S. M. (2017). The MCL-1 inhibitor S63845: an exciting new addition to the armoury of anti-cancer agents. Journal of Xiangya Medicine, 2(6), 53.
DOI Scopus3
2017 Powell, J., Lewis, A., Zhu, W., Toubia, J., Pitman, M., Wallington-Beddoe, C., . . . Pitson, S. (2017). Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.. Blood, 129(6), 771-782.
DOI Scopus86 WoS80 Europe PMC74
2017 Zhu, W., Gliddon, B., Jarman, K., Moretti, P., Tin, T., Parise, L., . . . Pitson, S. (2017). CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1. Oncogene, 36(18), 2619-2627.
DOI Scopus29 WoS27 Europe PMC19
2017 Hein, N., Cameron, D., Hannan, K., Nguyen, N., Fong, C., Sornkom, J., . . . Hannan, R. (2017). Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 129(21), 2882-2895.
DOI Scopus72 WoS73 Europe PMC67
2016 Neubauer, H. A., Pham, D. H., Zebol, J. R., Moretti, P. A. B., Peterson, A. L., Leclercq, T. M., . . . Pitson, S. M. (2016). An oncogenic role for sphingosine kinase 2. Oncotarget, 7(40), 64886-64899.
DOI Scopus54 WoS50 Europe PMC52
2016 Smith, A. M., Dun, M. D., Lee, E. M., Harrison, C., Kahl, R., Flanagan, H., . . . Verrills, N. M. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7(30), 47465-47478.
DOI Scopus42 WoS41 Europe PMC35
2015 Lee, E., Yee, D., Busfield, S., McManus, J., Cummings, N., Vairo, G., . . . Lock, R. (2015). Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica, 100(7), 914-926.
DOI Scopus60 WoS53 Europe PMC50
2015 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., Leclercq, T., Hughes, T., & White, D. (2015). Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia, 29(1), 76-85.
DOI Scopus30 WoS29 Europe PMC26
2015 Pitman, M., Powell, J., Coolen, C., Moretti, P., Zebol, J., Pham, D., . . . Pitson, S. (2015). A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget, 6(9), 7065-7083.
DOI Scopus65 WoS64 Europe PMC56
2014 Wallington-Beddoe, C., Powell, J., Tong, D., Pitson, S., Bradstock, K., & Bendall, L. (2014). Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression. Cancer Research, 74(10), 2803-2815.
DOI Scopus71 WoS65 Europe PMC63
2014 Pham, D., Powell, J., Gliddon, B., Moretti, P., Tsykin, A., Van der Hoek, M., . . . Pitson, S. (2014). Enhanced expression of transferrin receptor 1 contributes to oncogenic signalling by sphingosine kinase 1. Oncogene, 33(48), 5559-5568.
DOI Scopus26 WoS25 Europe PMC23
2013 Schafranek, L., Nievergall, E., Powell, J., Hiwase, D., White, D., Hughes, T., & Leclercq, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a BCR-ABL-dependent, but JAK2-independent manner. Blood, 122(21), 2705.
DOI WoS1
2013 Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14.
DOI Scopus20 WoS17 Europe PMC21
2013 Lonic, A., Powell, J., Kong, Y., Thomas, D., Holien, J., Truong, N., . . . Guthridge, M. (2013). Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein Kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. Journal of Biological Chemistry, 288(21), 14874-14885.
DOI Scopus16 WoS15 Europe PMC15
2013 Thomas, D., Powell, J., Vergez, F., Segal, D., Nguyen, N., Baker, A., . . . Guthridge, M. (2013). Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 122(5), 738-748.
DOI Scopus57 WoS56 Europe PMC50
2013 Powell, J., Pitman, M., Coolen, C., Zhu, W., Lewis, I., D'Andrea, R., . . . Lopez, A. (2013). Targeting sphingosine kinase as a therapy for acute myeloid leukaemia. Experimental Hematology, 41(8), S54.
DOI
2013 Thomas, D., Powell, J., Vergez, F., Barry, E. F., Sarry, J. E., Truong, N., . . . Guthridge, M. A. (2013). THERAPEUTIC TARGETING OF PI3K AND CDK9 IN AML. ANNALS OF HEMATOLOGY, 92, S17.
2011 Pitson, S., Powell, J., & Bonder, C. (2011). Regulation of sphingosine kinase in hematological malignancies and other cancers. Anti-Cancer Agents in Medicinal Chemistry, 11(9), 799-809.
DOI Scopus22 WoS22 Europe PMC19
2010 Roberts, K. G., Smith, A. M., McDougall, F., Carpenter, H., Horan, M., Neviani, P., . . . Verrills, N. M. (2010). Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Research, 70(13), 5438-5447.
DOI Scopus125 WoS122 Europe PMC99
2010 Hiwase, D., White, D., Powell, J., Saunders, V., Zrim, S., Frede, A., . . . Hughes, T. (2010). Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors. Leukemia, 24(4), 771-778.
DOI Scopus48 WoS42 Europe PMC40
2009 Powell, J., Thomas, D., Barry, E., Kok, C., McClure, B., Tsykin, A., . . . Guthridge, M. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 114(23), 4859-4870.
DOI Scopus53 WoS51 Europe PMC49
2009 Barry, E., Felquer, F., Powell, J., Biggs, L., Stomski, F., Urbani, A., . . . Guthridge, M. (2009). 14-3-3:Shc scaffolds integrate phosphoserine and phosphotyrosine signaling to regulate phosphatidylinositol 3-kinase activation and cell survival. Journal of Biological Chemistry, 284(18), 12080-12090.
DOI Scopus35 WoS32 Europe PMC29
2008 Davis, A., Carr, J., Bagley, C., Powell, J., Warrilow, D., Harrich, D., . . . Li, P. (2008). Human Immunodeficiency Virus type-1 reverse transcriptase exists as post-translationally modified forms in virions and cells. Retrovirology, 5(1), 115-1-115-12.
DOI Scopus8 WoS8 Europe PMC8
2008 Neilsen, P., Cheney, K., Li, C., Chen, D., Noll, J., Schulz, R., . . . Callen, D. (2008). Identification of ANKRD11 as a p53 coactivator. Journal of Cell Science, 121(21), 3541-3552.
DOI Scopus75 WoS71 Europe PMC68
2008 Hansen, G., Hercus, T., Mc Clure, B., Stomski, F., Dottore, M., Powell, J., . . . Parker, M. (2008). The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell, 134(3), 496-507.
DOI Scopus270 WoS251 Europe PMC221
2006 Guthridge, M., Powell, J., Barry, E., Stomski, F., Mc Clure, B., Ramshaw, H., . . . Lopez, A. (2006). Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO Journal, 25(3), 479-489.
DOI Scopus72 WoS71 Europe PMC69
2005 Kumar, R., Neilsen, P., Crawford, J., McKirdy, R., Lee, J., Powell, J., . . . Callen, D. (2005). FBXO31 is the chromosome 16q24.3 senescence gene, a candidate breast tumor suppressor, and a component of an SCF complex. Cancer Research, 65(24), 11304-11313.
DOI Scopus74 WoS74 Europe PMC63
2002 Powell, J., Gardner, A., Bais, A., Hinze, S., Baker, E., Whitmore, S., . . . Kremmidiotis, G. (2002). Sequencing, transcript identification, and quantitative gene expression profiling in the breast cancer loss of heterozygosity region 16q24.3 reveal three potential tumor-suppressor genes. Genomics, 80(3), 303-310.
DOI Scopus41 WoS41 Europe PMC34
2002 Kochetkova, M., McKenzie, O., Bais, A., Martin, J., Secker, G., Seshadri, R., . . . Callen, D. (2002). CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3. Cancer Research, 62(16), 4599-4604.
Scopus62 WoS61 Europe PMC52
2001 Cleton-Jansen, A., Callen, D., Seshadri, R., Goldup, S., McCallum, B., Crawford, J., . . . Cornelisse, C. (2001). Loss of heterozygosity mapping at chromosome arm 16q in 712 breast tumors reveals factors that influence delineation of candidate regions. Cancer Research, 61(3), 1171-1177.
Scopus91 WoS92 Europe PMC75
2000 Sims, N. R., Anderson, M. F., Hobbs, L. M., Powell, J. A., & Zaidan, E. (2000). Brain mitochondrial responses to postischemic reperfusion: A role for calcium and hydrogen peroxide?. Developmental Neuroscience, 22(5-6), 366-375.
DOI Scopus9 Europe PMC6
2000 Sims, N. R., Anderson, M. F., Hobbs, L. M., Kong, J. Y., Phillips, S., Powell, J. A., & Zaidan, E. (2000). Impairment of brain mitochondrial function by hydrogen peroxide. Molecular Brain Research, 77(2), 176-184.
DOI Scopus50 Europe PMC34
1998 Sims, N. R., Williams, V. K., Zaidan, E., & Powell, J. A. (1998). The antioxidant defences of brain mitochondria during short-term forebrain ischemia and recirculation in the rat. Molecular Brain Research, 60(2), 141-149.
DOI Scopus23 Europe PMC14
1988 CARPENTER, R. G., GARDNER, A., HARRIS, J., JUDD, M., LEWRY, J., MADDOCK, C. R., . . . TAYLOR, E. M. (1988). Prevention of Unexpected Infant Death: A Review of Risk‐Related Intervention in Six Centers. Annals of the New York Academy of Sciences, 533(1), 96-105.
DOI Scopus9 Europe PMC7
1985 Powell, J. (1985). Cot deaths: keeping watch.. Community Outlook, 15-19.
Scopus1
1984 Powell, J. (1984). Cot Deaths — can they be prevented?. Journal of the Royal Society for the Promotion of Health, 104(6), 203-205.
DOI Europe PMC1
1983 Powell, J., Machin, D., & Kershaw, C. R. (1983). Unexpected sudden infant deaths in Gosport--some comparisons between service and civilian families.. Journal of the Royal Naval Medical Service, 69(3), 141-150.
DOI Scopus5 Europe PMC4

Year Citation
2017 Lewis, A. C., Powell, J. A., & Pitson, S. M. (2017). The Emerging Role of Sphingolipids in Cancer Stem Cell Biology. In Stem Cell Biology and Regenerative Medicine (Vol. Part F4899, pp. 151-170). Springer International Publishing.
DOI Scopus1

Year Citation
2014 Brown, A. L., Sadras, T., Engler, G. A., Tunningley, R., Kofler, J., Leo, P. J., . . . D'Andrea, R. J. (2014). An ENU Mutagenesis Screen of FLT3-ITD Knock-in Mice Identifies Novel Gene Mutations That Lead to an Exacerbated Myeloproliferative Neoplasm. In BLOOD Vol. 124 (pp. 3 pages). San Francisco, CA: AMER SOC HEMATOLOGY.
2010 Thomas, D., Powell, J. A., Barry, E. F., Woodcock, J., Ekert, P. G., Green, B. D., . . . Guthridge, M. A. (2010). THE PROTEIN KINASE ACTIVITY OF PHOSPHOINOSITIDE 3-KINASE ALPHA PROMOTES AUTONOMOUS CELL SURVIVAL IN AML STEM/PROGENITOR CELLS. In EXPERIMENTAL HEMATOLOGY Vol. 38 (pp. S87). Melbourne, AUSTRALIA: ELSEVIER SCIENCE INC.
2010 Powell, J. A., Thomas, D., Barry, E. F., Kok, C. H., Ma, L. Y., To, L. B., . . . Guthridge, M. A. (2010). TARGETING CELL SURVIVAL PATHWAYS IN ACUTE MYELOID LEUKEMIA. In EXPERIMENTAL HEMATOLOGY Vol. 38 (pp. S60). Melbourne, AUSTRALIA: ELSEVIER SCIENCE INC.
2009 Guthridge, M., Thomas, D., Barry, E. F., Chung, K. H., McClure, B. J., To, L. B., . . . Powell, J. A. (2009). Expression Profiling of a Hemopoietic Cell Survival Transcriptome Identifies a Functional Prognostic Gene Signature in Normal Karyotype AML.. In BLOOD Vol. 114 (pp. 647). New Orleans, LA: AMER SOC HEMATOLOGY.
2009 Hiwase, D. K., White, D. L., Powell, J. A., Saunders, V. A., Zrim, S., Frede, A., . . . Hughes, T. (2009). Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. In BLOOD Vol. 114 (pp. 1258-1259). New Orleans, LA: AMER SOC HEMATOLOGY.
2008 Thomas, D., Woodcock, J., Powell, J. A., Barry, E. F., Lopez, A. F., & Guthridge, M. A. (2008). Lipid and Protein Substrates of PI3K in Cytokine Receptor Survival Signalling: Deregulation in Leukemia. In BLOOD Vol. 112 (pp. 1315). San Francisco, CA: AMER SOC HEMATOLOGY.
WoS3
2008 Thomas, D., Powell, J. A., Barry, E. F., To, L. B., Lopez, A., & Guthridge, M. A. (2008). A Molecular Signature for a Cytokine Receptor Survival Pathway in AML Identifies Unique Prognostic Indicators and Therapeutic Targets. In BLOOD Vol. 112 (pp. 995). San Francisco, CA: AMER SOC HEMATOLOGY.
2005 Thomas, D., Powell, J., Lee, S. H., Lopez, A. F., & Mark, G. (2005). Primary acute myeloid leukemic blasts display constitutive serine 585 phosphorylation within the 14-3-3 binding motif of the GM-CSF/IL-3 receptor required for survival signalling.. In BLOOD Vol. 106 (pp. 25A). Atlanta, GA: AMER SOC HEMATOLOGY.
2005 Powell, J. A., Thomas, D., Lee, S. H., Lopez, A. F., & Guthridge, M. A. (2005). Constitutive serine-585 phosphorylation of the GM-CSF receptor and the deregulation of survival signalling in AML blasts. In EXPERIMENTAL HEMATOLOGY Vol. 33 (pp. 74). Univ Glasgow, Glasgow, SCOTLAND: ELSEVIER SCIENCE INC.
2001 Callen, D. F., Bais, A., Crawford, J., Gardner, A., McKenzie, O., Powell, J., . . . Kremmidiotis, G. (2001). Identification of putative breast cancer tumour suppressor gene at 16q24.3.. In AMERICAN JOURNAL OF HUMAN GENETICS Vol. 69 (pp. 205). UNIV CHICAGO PRESS.

Year Citation
2022 Subramanian, S., Thoms, J. A. I., Huang, Y., Jacquelin, S., Powell, J., Pitson, S. M., & Pimanda, J. E. (2022). Comparative analysis of genome-scale gene regulatory networks in human hematopoietic stem and myeloid progenitor fractions. Poster session presented at the meeting of Blood. US: American Society of Hematology.
DOI
2013 Wallington-Beddoe, C. T., Pitson, S. M., Powell, J. A., Bradstock, K. F., & Bendall, L. J. (2013). Evaluation Of Sphingosine Kinase 1 As a Therapeutic Target In B-Lineage Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. New Orleans, LA: AMER SOC HEMATOLOGY.
DOI
2013 White, D. L., Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D., Leclercq, T., & Hughes, T. (2013). STAT5 is a critical component of the time-dependent sensitivity of CML cells to TKI treatment in a Bcr-Abl-dependent, but JAK2-independent manner.. Poster session presented at the meeting of American Society of Haematology. New Orleans, USA.
2012 Schafranek, L., Nievergall, E., Powell, J. A., Hiwase, D. K., White, D. L., & Hughes, T. P. (2012). Commitment of CML Cells to Apoptotic Cell Death Depends On the Length of Exposure to Das and the Level of STAT5 Activity. Poster session presented at the meeting of BLOOD. Atlanta, GA: AMER SOC HEMATOLOGY.
DOI WoS3
2012 Wallington-Beddoe, C. T., Bradstock, K. F., & Bendall, L. J. (2012). Identification of Sphingosine Kinases As Therapeutic Targets in B-Lineage Acute Lymphoblastic Leukemia. Poster session presented at the meeting of BLOOD. GA, Atlanta: AMER SOC HEMATOLOGY.
DOI WoS2

  • Bioengineering a Superior Humanized Haematopoietic Niche Derived from Mesenchymal Stem Cells for Pre-Clinical Avatar Cancer Trials, MRFF-Stem Cell Therapies Mission, 01/08/2023 - 31/01/2026

  • Examining the pathogenic bone marrow microenvironment, HSC stress, and targeting clonal evolution to prevent development of leukaemia in predisposed individuals, Leukaemia Foundation - Grant in Aid (National Research Program), 10/07/2023 - 09/05/2025

  • Stereotactic alignment and injection system for the generation of xenografts of human brain tumours into the brains of mice for pre-clinical testing of new and existing therapeutics, Neurosurgical Research Foundation, 01/01/2018 - 31/12/2018

Connect With Me

External Profiles

Other Links